As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...

Moreover, Novo is advancing with new GLP-1 agonist formulations for both diabetes and obesity, which are much further along than what Lilly presented in its announcement. Oral semaglutide ...

A recently published report by the Brookings Institute found that these foreign suppliers are making up their own standards for manufacturing "semaglutide," and Novo Nordisk's testing has revealed ...